News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
38,590 Results
Type
Article (1810)
Company Profile (5)
Press Release (36775)
Section
Business (15657)
Career Advice (80)
Deals (2771)
Drug Delivery (4)
Drug Development (3893)
Employer Resources (3)
FDA (791)
Job Trends (826)
News (22237)
Policy (1211)
Tag
Academia (50)
Accelerated approval (2)
Adcomms (1)
Allergies (6)
Alliances (1531)
ALS (11)
Alzheimer's disease (66)
Antibody-drug conjugate (ADC) (21)
Approvals (832)
Artificial intelligence (22)
Autoimmune disease (3)
Automation (1)
Bankruptcy (16)
Best Places to Work (680)
Biosimilars (6)
Biotechnology (3)
Bladder cancer (10)
Breast cancer (69)
Cancer (329)
Cardiovascular disease (27)
Career advice (72)
Career pathing (2)
CAR-T (4)
CDC (1)
Cell therapy (26)
Cervical cancer (2)
Clinical research (3708)
Collaboration (58)
Compensation (62)
Complete response letters (1)
COVID-19 (66)
C-suite (13)
Cystic fibrosis (7)
Data (414)
Depression (4)
Diabetes (33)
Diagnostics (407)
Digital health (3)
Diversity, equity & inclusion (1)
Drug discovery (7)
Drug pricing (8)
Drug shortages (3)
Duchenne muscular dystrophy (10)
Earnings (14121)
Editorial (1)
Employer resources (2)
Events (3842)
Executive appointments (18)
FDA (1077)
Fibrodysplasia Ossificans Progressiva (1)
Frontotemporal dementia (1)
Funding (61)
Gene editing (6)
Generative AI (1)
Gene therapy (19)
GLP-1 (64)
Government (114)
Guidances (147)
Healthcare (1041)
HIV (6)
IgA nephropathy (1)
Immunology and inflammation (10)
Immuno-oncology (2)
Indications (8)
Infectious disease (78)
Inflammatory bowel disease (14)
Influenza (4)
Intellectual property (12)
Interviews (20)
IPO (1917)
Job creations (192)
Job search strategy (43)
JPM (5)
Kidney cancer (1)
Labor market (11)
Layoffs (37)
Legal (253)
Liver cancer (2)
Lung cancer (59)
Lymphoma (48)
Manufacturing (38)
MASH (8)
Medical device (853)
Medtech (859)
Mergers & acquisitions (897)
Metabolic disorders (84)
Multiple sclerosis (15)
NASH (1)
Neurodegenerative disease (11)
Neuropsychiatric disorders (5)
Neuroscience (129)
NextGen: Class of 2026 (229)
Non-profit (125)
Obesity (44)
Opinion (4)
Ovarian cancer (9)
Pain (8)
Pancreatic cancer (19)
Parkinson's disease (8)
Partnered (1)
Patents (19)
Patient recruitment (5)
Peanut (4)
People (1124)
Pharmacy benefit managers (1)
Phase 1 (851)
Phase 2 (1539)
Phase 3 (1514)
Pipeline (749)
Policy (3)
Postmarket research (178)
Preclinical (267)
Press Release (1)
Prostate cancer (5)
Psychedelics (2)
Radiopharmaceuticals (14)
Rare diseases (32)
Real estate (204)
Recruiting (2)
Regulatory (1053)
Reports (5)
Research institute (54)
Resumes & cover letters (20)
RSV (4)
Schizophrenia (14)
Series A (5)
Series B (6)
Service/supplier (1)
Sickle cell disease (5)
Spinal muscular atrophy (17)
Startups (128)
Stomach cancer (1)
Supply chain (2)
Tariffs (4)
The Weekly (1)
Vaccines (20)
Venture capital (7)
Weight loss (30)
Women's health (5)
Date
Today (5)
Last 7 days (42)
Last 30 days (126)
Last 365 days (2298)
2026 (165)
2025 (2290)
2024 (2553)
2023 (2683)
2022 (3033)
2021 (3030)
2020 (2816)
2019 (2109)
2018 (1733)
2017 (1544)
2016 (1167)
2015 (1394)
2014 (990)
2013 (690)
2012 (729)
2011 (844)
2010 (6529)
Location
Africa (29)
Alabama (4)
Arizona (12)
Asia (2142)
Australia (228)
California (793)
Canada (200)
China (61)
Colorado (36)
Connecticut (36)
Delaware (69)
Europe (4915)
Florida (96)
Georgia (32)
Idaho (4)
Illinois (75)
India (5)
Indiana (78)
Japan (34)
Kansas (7)
Kentucky (4)
Louisiana (5)
Maine (7)
Maryland (83)
Massachusetts (480)
Michigan (23)
Minnesota (36)
Missouri (5)
Montana (2)
Nebraska (1)
Nevada (3)
New Hampshire (10)
New Jersey (283)
New Mexico (2)
New York (262)
North Carolina (94)
Northern California (451)
Ohio (19)
Oregon (2)
Pennsylvania (172)
Puerto Rico (2)
Rhode Island (1)
South America (60)
South Carolina (5)
Southern California (264)
Tennessee (7)
Texas (94)
United States (2866)
Utah (29)
Virginia (8)
Washington D.C. (2)
Washington State (58)
Wisconsin (5)
38,590 Results for "125".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Immunology and inflammation
J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark
J&J paid Numab Therapeutics $1.25 billion upfront for the asset in 2024 based on the belief that its dual mechanism of action could improve on existing therapies.
January 5, 2026
·
2 min read
·
Nick Paul Taylor
Press Releases
enGene Announces Expanded $125 Million Debt Facility with Hercules Capital, Inc.
January 21, 2026
·
10 min read
Press Releases
Immatics Announces $125 Million Underwritten Offering
December 5, 2025
·
3 min read
Venture capital
Ambros Launches With $125M To Bring Italian Non-Opioid Pain Drug to America
Ambros Therapeutics’ non-opioid bisphosphonate analgesic, already approved in Italy, will soon begin a pivotal test in the U.S.
December 16, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Amphix Bio raises $12.5M seed round to advance peptide drug platform
December 19, 2025
·
2 min read
Press Releases
Diagonal Therapeutics Announces Oversubscribed $125 Million Series B Financing to Advance Clinical Development of Disease-Modifying, Clustering Antibody Pipeline
January 8, 2026
·
5 min read
Collaboration
Crescent, Kelun-Biotech Swap Therapies in ADC-Bispecific Deal Worth Up To $1.25B
The partnership will focus on Crescent’s PD-1/VEGF inhibitor CR-001 and Kelun-Biotech’s SKB105, both of which the companies plan to push into Phase I/II development for solid tumors early next year.
December 4, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
November 18, 2025
·
5 min read
Press Releases
Myosin Therapeutics Receives FDA Fast Track Designation for MT-125 in Glioblastoma
October 22, 2025
·
2 min read
Press Releases
C4 Therapeutics Announces Pricing of $125 Million Underwritten Offering
October 17, 2025
·
6 min read
1 of 3,859
Next
